The Effect of LY2409021 on Blood Pressure and Pulse Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Subjects With Type 2 Diabetes Mellitus
Phase of Trial: Phase II
Latest Information Update: 14 Jun 2016
At a glance
- Drugs Adomeglivant (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Eli Lilly
- 07 Jun 2017 Biomarkers information updated
- 09 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Sep 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.